Analyst Reco. Abbott Laboratories

Equities

ABT

US0028241000

Real-time Estimate Cboe BZX Other stock markets 11:18:11 2024-05-03 am EDT			5-day change	1st Jan Change
105.7 ^USD	-0.19%		-1.73%	-4.00%

Apr. 29	Abbott's Dissolving Stent Gets FDA Approval For Arteries Below the Knee	MT
Apr. 26	Dexcom's profit beats estimates on strong glucose monitor demand	RE

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Daiwa Securities Trims Abbott Laboratories Price Target to $125 From $126	Apr. 23	MT
Barclays Adjusts Abbott Laboratories' Price Target to $140 From $141, Maintains Overweight Rating	Apr. 22	MT
UBS Raises Abbott Laboratories Price Target to $143 from $136, Buy Rating Kept	Apr. 19	MT
RBC Lowers Price Target on Abbott Laboratories to $125 From $128, Keeps Outperform Rating	Apr. 18	MT
Raymond James Adjusts Abbott Laboratories' Price Target to $124 From $127, Keeps Outperform Rating	Apr. 18	MT
Citigroup Raises Price Target on Abbott Laboratories to $128 From $126, Keeps Buy Rating	Apr. 03	MT
Barclays Raises Abbott Laboratories' Price Target to $141 From $133, Keeps Overweight Rating	Jan. 26	MT
Raymond James Adjusts Price Target on Abbott Laboratories to $127 From $124, Maintains Outperform Rating	Jan. 25	MT
Citigroup Raises Abbott Laboratories Price Target to $126 From $123, Maintains Buy Rating	Jan. 25	MT
Bernstein Raises Abbott Laboratories Price Target to $133 From $125, Maintains Outperform Rating	Jan. 25	MT
JPMorgan Raises Abbott Laboratories Price Target to $125 From $122, Maintains Overweight Rating	Jan. 25	MT
UBS Raises Abbott Laboratories Price Target to $136 From $122, Maintains Buy Rating	Jan. 22	MT
Wall St Week Ahead-Maligned US real estate sector draws buyers eyeing rate cuts	Jan. 21	RE
Wall St Week Ahead-Maligned US real estate sector draws buyers eyeing rate cuts	Jan. 19	RE
RBC Adjusts Abbott Laboratories' Price Target to $128 From $119, Keeps Outperform Rating	Jan. 11	MT
Raymond James Raises Abbott Laboratories' Price Target to $124 From $110, Maintains Outperform Rating	Jan. 03	MT
Wells Fargo Raises Price Target on Abbott Laboratories to $121 From $116, Maintains Overweight Rating	Dec. 13	MT
UBS Raises Abbott Laboratories Price Target to $122 From $118, Maintains Buy Rating	23-10-19	MT
Wells Fargo Cuts Price Target on Abbott Laboratories to $116 From $136, Maintains Overweight Rating	23-10-19	MT
Morningstar Upgrades Abbott Laboratories to Buy From Hold, $104 Price Target	23-10-19	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Abbott Laboratories

Equities

ABT

US0028241000

Analyst Reco.

Filters